In summary, our results suggest that B7-H3 can serve as an independent prognostic factor for COAD patients who receive adjuvant chemotherapy, and dual targeting of the B7-H3 and EGFR signaling pathways may be a promising strategy for treating B7-H3-expressing COAD patients. Here, CD276 is linked to colon adenocarcinoma.